Massachusetts Insurers Cut GLP-1 Coverage, Pushing 112,000 Off Drugs Tied to Heart Protection

More than 112,000 commercially insured Massachusetts residents lost coverage for GLP-1 weight-loss drugs in a single quarter this year, and a pair of recent findings raises a pointed question about what comes next for their hearts.

<cite index="20-3,20-4">Private health insurers paid for over 100,000 fewer Massachusetts residents' GLP-1 drugs for obesity earlier this year, after they restricted coverage, according to a state report released Thursday. The number of people receiving drugs such as Wegovy or Zepbound through their insurance for obesity plunged by half after insurers largely stopped automatically covering that purpose in January.</cite>

The numbers come from the Massachusetts Health Policy Commission, a state agency that presented the data at a board meeting September 17. <cite index="22-6">Gross spending on the drugs before manufacturer rebates and discounts reached over $2.3 billion in 2025, while net spending on GLP-1 drugs for commercially insured residents totaled nearly $1 billion.</cite> Carriers said years of record losses on the drugs forced their hand.

<cite index="22-7">Plans that discontinued coverage of GLP-1s specifically for weight loss in 2026 included the Group Insurance Commission, MassHealth, Blue Cross Blue Shield of Massachusetts, Point32Health, and Mass General Brigham Health Plan.</cite> <cite index="20-8">The insurers all continue to cover the drugs for people who have diabetes or other conditions, but people with obesity alone largely no longer have coverage.</cite>

For those patients, the out-of-pocket math is steep. <cite index="20-9">Out-of-pocket costs can run $150 to upwards of $400 per month for commercially available options.</cite> <cite index="21-1">The list price of a brand-name GLP-1 runs roughly $1,000 to $1,350 per month as of June 2026.</cite>

The coverage pullback lands against a backdrop of accumulating evidence that stopping these medications carries real cardiac consequences. A study published in BMJ Medicine in March, drawn from more than 333,000 adults with type 2 diabetes treated through the Veterans Health Administration, found the risks mount faster than many clinicians expected.

<cite index="12-3,12-7">A large study found that heart risks begin to return as soon as six months after stopping a GLP-1, and may be almost completely eclipsed as soon as a year and a half after stopping.</cite> <cite index="12-10">Compared with those who remained on the drug, people who discontinued had a 4% increase in heart risks six months after going off, a 14% increase at one year, and a 22% increase by the second year off the medication, which meant the benefits they'd seen had virtually been erased.</cite>

There's an additional wrinkle the BMJ Medicine paper surfaces. <cite index="17-4,17-5">As little as one year off the drug was more than enough for study participants to lose benefits cultivated over years of continuous treatment, and once lost, those gains were not fully restored by resuming treatment.</cite> The researchers described this dynamic as a kind of metabolic whiplash.

The study's lead author, Dr. Ziyad Al-Aly, a clinical epidemiologist at Washington University School of Medicine in St. Louis, said the cardiovascular protection from these drugs builds slowly and erodes fast. <cite index="16-3">Al-Aly said providers and patients contemplating a GLP-1 should understand that people need to stay on treatment "for the long haul," not for just a few months or even years.</cite>

That's a harder argument to make when coverage disappears. <cite index="27-3">About 56% of current GLP-1 users, including 55% of those with insurance, say the drugs are difficult to afford, and 14% stopped because of cost, according to a KFF survey from late 2025.</cite> Real-world discontinuation rates run far above what clinical trials show: <cite index="27-5">insurance-claims data show about 65% of users without type 2 diabetes and about 47% with diabetes discontinue within one year.</cite>

The Massachusetts picture is one version of a national pattern. <cite index="24-6">ACA marketplace plans have also been reducing access to GLP-1s for weight loss, with only 26 of 300 carriers offering coverage, and overall coverage rates falling from 3.6 million enrollees in 2024 to 2.8 million in 2026.</cite>

What the Massachusetts Health Policy Commission report doesn't capture is what happened to the patients who lost coverage. <cite index="20-1,20-2">The report does not include data on whether commercial insurance members continued to get GLP-1s by paying out-of-pocket, and the question of what happened to those folks remains open.</cite>

For patients with obesity who were on these drugs for cardiac risk reduction, not just weight loss, that gap matters. The BMJ Medicine study was conducted in adults with type 2 diabetes, so its findings don't translate directly to every patient losing coverage now. But the underlying biology, a rapid loss of protection once the drug stops, applies across indications. Clinicians who've been prescribing these drugs for cardiovascular benefit will need to have a different conversation with patients when the insurance letter arrives.

Sources cited:
- Massachusetts Health Policy Commission report, via Boston Globe (https://www.bostonglobe.com/2026/09/17/business/health-insurers-covered-112000-fewer-mass-residents-glp-1-weight-loss-drugs-this-year-report-finds/)
- WWLP / State House News Service, HPC board meeting, Sept. 17, 2026 (https://www.wwlp.com/news/massachusetts/coverage-changes-spark-sharp-decline-in-glp-1-usage/)
- GBH News, Sharp decline in GLP-1 usage, Sept. 17, 2026 (https://www.wgbh.org/news/health/2026-09-17/sharp-decline-in-glp-1-usage-in-2026-as-insurance-companies-drop-coverage)
- BMJ Medicine, Xie, Choi, Al-Aly; GLP-1RA discontinuation and cardiovascular risk, March 18, 2026 (https://medicine.washu.edu/news/stopping-glp-1-drugs-can-quickly-erase-cardiovascular-benefits/)
- CNN Health, Heart benefits fade after stopping GLP-1 medications (https://www.cnn.com/2026/03/18/health/glp-1-medications-heart-benefits-study)
- Axios, The dangerous risks of stopping Ozempic and GLP-1s, Sept. 21, 2026 (https://www.axios.com/2026/09/21/ozempic-glp-glp1s-weight-loss-side-effects-risks)
- MealFan, GLP-1 Statistics 2026 (KFF survey data) (https://mealfan.com/glp-1-statistics-2026/)
- Definitive HC, GLP-1 coverage cuts and payer policy (https://www.definitivehc.com/blog/what-glp1-coverage-cuts-could-mean-for-prescribing-access-utilization)